论文部分内容阅读
黑素瘤是常见的皮肤恶性肿瘤,其恶性程度高,侵袭性强,患者预后极差。但自2011年以来多个新药陆续上市,尤其是免疫治疗药物优势凸显。例如,CTLA-4抗体药物(ipilimumab)和PD-1/PD-L1抗体药物(nivolumab,pembrolizumab)大幅提高黑素瘤患者的客观有效率;IL-2瘤内给药和L19-IL2融合蛋白药物也取得令人瞩目的临床进展。本文从免疫检查点抑制剂、被动免疫、主动免疫、过继免疫等方面,对迄今已上市和即将上市的黑素瘤免疫治疗药物进行介绍,利于临床用药,也为新药研发提供思路。
Melanoma is a common skin cancer, its high degree of malignancy, aggressive, poor prognosis in patients. However, many new drugs have been listed since 2011, especially the advantages of immunotherapy drugs. For example, CTLA-4 antibody (ipilimumab) and PD-1 / PD-L1 antibody (nivolumab, pembrolizumab) significantly improve the objective efficiency of melanoma patients; IL-2 intratumoral administration and L19-IL2 fusion protein drug Also made remarkable clinical progress. This article from the immune checkpoint inhibitor, passive immunization, active immunization, adoptive immunity, etc., has so far listed and upcoming introduction of melanoma immunotherapy drugs, which is conducive to clinical medication, but also provide ideas for the development of new drugs.